When is Chemotherapy indicated in Advanced Luminal Breast Cancer?
|
|
- Chrystal Holmes
- 6 years ago
- Views:
Transcription
1 When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore Education Senior Principal Investigator Cancer Science Institute, Singapore Research
2 Who still cares about Chemotherapy for Luminal Breast Cancers in this era of CDK4/6 Inhibitors? Chemotherapy CDK4/6 inhibitor
3 What is Luminal Breast Cancer? Intrinsic Subtypes by Gene Expression Profiling Molecular testing (e.g., PAM50) not routinely done in the clinic Surrogate markers usually used (ER, PR, HER2, grade, Ki67) LUMINAL A HER2 - ER+/PR+ (high expression) Low grade Low proliferative index (Ki67) Concordance between surrogate markers vs gene expression profiling 60-80% LUMINAL B (Heterogeneous group) HER2 - ER/PR+ (low expression) OR ER+/PR- OR ER-/PR+ High grade/ High proliferative index (Ki67) HER2 + ER and/or PR + Low/high grade Low/high proliferative index Perou et al. PNAS 2001, 98(19):
4 Systemic Treatment Options for Luminal Breast Cancers LUMINAL A HER2 - ER+/PR + Low grade Low proliferative index (Ki67) HER2 - LUMINAL B ER/PR+ (low expression) OR ER+/PR- OR ER-/PR+ High grade/ High proliferative index HER2 + ER and/or PR + Low/high grade Low/high proliferative index Endocrine Therapy* Chemotherapy Endocrine Therapy Chemotherapy Anti-HER2 Therapy *+/- biological agent (CDK4/6 inhibitors, mtor inhibitors)
5 General Principles in Treatment of Metastatic Breast Cancer Treatment goals (non-curative): Prolong overall survival if possible Relieve symptoms, preserve quality of life Treatment with higher response rate is preferred if tumor burden is high (to treat or prevent crisis) Sequential treatment in metastatic breast cancer Treatment 1 Treatment 2 Treatment 3 Treatment 4 Treatment 5 Treatment that prolongs overall survival is preferentially given (usually in early line) If none of the available treatment options improves overall survival, then the least toxic effective regimen is preferred
6 Chemotherapy vs Endocrine Therapy in Advanced Luminal Breast Cancers 1. Does chemotherapy confer a survival advantage (compared to endocrine therapy)? 2. Is there a subset of luminal breast cancers for which chemotherapy confers survival advantage? 3. Does chemotherapy have higher response rate than endocrine therapy to be a better choice when there is an impending crisis? 4. Is the tumor (still) sensitive to endocrine therapy?
7 Chemotherapy alone vs Endocrine Therapy alone for Metastatic Breast Cancer Cochrane review; 10 trials ( ) OS data in 6 trials (n=692) Favors endocrine therapy Favors chemo More toxicities with chemotherapy No difference in overall mortality Wilcken et al. Cochrane Library 2003
8 Chemotherapy vs Endocrine Therapy in Advanced Luminal Breast Cancers 1. Does chemotherapy confer a survival advantage (compared to endocrine therapy)? 2. Is there a subset of luminal breast cancers for which chemotherapy confers survival advantage? 3. Does chemotherapy have higher response rate than endocrine therapy to be a better choice when there is an impending crisis? 4. Is the tumor (still) sensitive to endocrine therapy?
9 HR+, HER2+ Metastatic Breast Cancer Anti-HER2 + Endocrine Therapy improved PFS but not OS HER2+, HR+ MBC (TAnDEM) N=207 (Phase 3 randomized) No prior chemo; prior hormonal therapy allowed R Anastrozole Trastuzumab + Anastrozole HER2+, HR+ MBC, n=219 No prior treatment for MBC R Letrozole Lapatinib + Letrozole PFS PFS 4.8 vs 2.4 months P= vs 3.0 months P=0.019 OS 28.5 vs 23.9 months, p=0.325 OS 33.3 vs 32.3 months, p=0.113 Kaufmann et al. J Clin Oncol, 2009; 27: ; Johnston et al. J Clin Oncol 2009; 27:
10 HER2+ Metastatic Breast Cancer Anti-HER2 + Chemotherapy improved PFS and OS HER2+ MBC, First-line N=469, 60% HR+ CLEOPATRA, HER2+ MBC First-line; N=808, 50% HR+ R Paclitaxel or anthracyclines Paclitaxel or anthracyclines R Trastuzumab + Docetaxel Trastuzumab + Docetaxel Trastuzumab Pertuzumab Median OS 20.3 vs 25.1 months, p=0.046 Chemo + Trastuzumab Chemo OS 40.8 vs 56.5 months HR 0.68 P<0.001 HR+ subset, HR 0.71 OS Slamon et al. NEJM 2001, 344: ; Swain et al. NEJM 2015, 372:
11 Impact of First-line Treatments on Survival of HER2+ Metastatic Breast Cancer Overall survival Pertuzumab + trastuzumab + docetaxel (any HR), 56 months (CLEOPATRA, 50% HR+) Trastuzumab + Endocrine (HR+), 30 months Endocrine Therapy alone (HR+), 30 months Trastuzumab + Chemo (any HR), 25 months Chemotherapy alone (any HR), 20 months * No trials comparing anti-her2 agent + chemotherapy vs anti-her2 agent + endocrine therapy for HR+/HER2+ MBC Anti-HER2 therapy + chemotherapy is the preferred initial treatment in HER2+ luminal breast cancer in view of overall survival benefit Exception: older patient with limited life expectancy from other co-morbidities, very low disease burden (e.g., bone only), highly endocrine sensitive
12 Chemotherapy vs Endocrine Therapy in Advanced Luminal Breast Cancers 1. Does chemotherapy confer a survival advantage (compared to endocrine therapy)? 2. Is there a subset of luminal breast cancers for which chemotherapy confers survival advantage? 3. Does chemotherapy have higher response rate than endocrine therapy to be a better choice when there is an impending crisis? 4. Is the tumor (still) sensitive to endocrine therapy?
13 Chemotherapy alone vs Endocrine Therapy alone for Metastatic Breast Cancer Cochrane review; 10 trials ( ) Treatment response data in 8 trials (n=817) Favors endocrine therapy Favors chemo Tumor Response Rate Very old trials HER2 status not known ER/PR status may not be known Favors chemotherapy Wilcken et al. Cochrane Library 2003
14 Chemotherapy vs Endocrine-based Therapy ER+ Breast Cancer (Neoadjuvant) Phase II randomized, N=239 Postmenopausal, ER+, Neoadjuvant R Letrozole or Exemestane x 3 months Doxorubicin/Paclitaxel x 4 cycles ORR Time to pcr response 64% 57 days 3% 64% 51 days 6% UNICANCER-NeoPAL Study Post-menopausal, Stage II-III ER+, HER2-; PAM50 luminal A or B N=106 randomized Luminal B: 89% ORR 75% pcr 4% Chemotherapy vs Endocrine therapy No difference in survival Higher response rate Shorter time to respond R Letrozole + palbociclib x 19 weeks FEC x 3 Docetaxel x 3 76% 6% Semiglazov et al. Cancer 2007;110(2):244-54; Cottu et al. ESMO 2017
15 Systemic Treatment of HR+ Advanced Breast Cancer Clinical Practice Guidelines (NCCN, ASCO, ESMO) Patients whose tumors express any level of hormone receptors should be offered endocrine therapy, unless there is immediately life-threatening disease (ASCO) or visceral crisis (NCCN), in which case chemotherapy would be indicated Sequential endocrine therapy is recommended in the absence of endocrine resistance Patridge et al. JCO 2014; 32: Rugo et al. JCO 2016, 34:
16 Chemotherapy vs Endocrine Therapy in Advanced Luminal Breast Cancers 1. Does chemotherapy confer a survival advantage (compared to endocrine therapy)? 2. Is there a subset of luminal breast cancers for which chemotherapy confers survival advantage? 3. Does chemotherapy have higher response rate than endocrine therapy to be a better choice when there is an impending crisis? 4. Is the tumor (still) sensitive to endocrine therapy?
17 Types of Endocrine Resistance IMPACT trial Post-menopausal ER+, n=330 R Tamoxifen x 12 weeks Anastrozole x 12 weeks Tamoxifen + Anastrozole x 12 weeks Serial biopsy at baseline, 2 weeks and 12 weeks to assess Ki67 (Ki67 is a marker of response to endocrine therapy) S U R G Acquired resistance De Novo Resistance Endocrine sensitive Dowsett et al. Clin Can Res 2005; 11(2): 951s-958s; Anderson et al. SABCS 2009
18 Key Questions about Endocrine Resistance in Metastatic Breast Cancer How common is this? Can these patients be reliably identified before treatment? When is the patient considered endocrine resistant (or refractory) such that further endocrine-based therapies will be futile? DE NOVO RESISTANCE ACQUIRED RESISTANCE (all patients, a matter of time)
19 How common is De Novo Endocrine Resistance in Metastatic Breast Cancer? FIRST-LINE ER+, HER2- CDK4/6i trials PALOMA-2 N=666 Treatment Letrozole Letrozole + Palbociclib No clinical benefit rate 30% 15% De novo resistance 30% endocrine therapy 20% endocrine + CDK4/6i MONALEESA-2 N=668 Letrozole Letrozole + Ribiociclib 30% 27% MONARCH-3 N=493 Letrozole or Anastrozole Letrozole or Anastrozole + Abemaciclib 28% 22% According to the guidelines*, only <5-10% of patients will be given first-line chemotherapy, but de novo resistance occurs in 20-30% of patients (i.e., progress within 3 months). Does this matter? *Start with endocrine therapy in the absence of life threatening disease Finn et al. NEJM 2016; 375: ; Hortobagyi et al NEJM 2016; 375: Goetz et al. J Clin Oncol 2017; 35: ; Turner et al. NEJM 2015; 373: ; Sledge et al. JCO 2017, 35(25):
20 Choosing the Wrong Treatment may result in Loss of Opportunity for Further Treatment After failure of first-line therapy, a proportion of patients cannot undergo second-line therapy due to rapid disease progression Study 2 nd line 3 rd line 4 th line 5 th line Dufresne et al, % 56% 25% 11% Tacca et al, % 68% 43% 23% Bernardo et al, % 82% 36% 11% Planchat et al, % 76% 56% 37% Jackish et al, % 70% 46% 27% About one-third of patients stop their treatment with each new line of therapy Harbeck, ABC4 2017; Dufresne et al, Breast Cancer Res Treat 2008, 107: 275-9; Tacca et al. Cancer Invest 2009; 27: 81-5; Bernardo et al. Cancer Res 2010; 70 (24 Suppl): 446s, Planchat et al, Breast 2011; 20: 574-8; Jackish et al, BMC Cancer, 2014; 14: 924
21 Can Primary Endocrine Resistance be reliably predicted? Endocrine sensitivity is a continuum, influenced by multiple factors High Low Low ER/PR EXPRESSION (percentage/intensity) GRADE PROLIFERATIVE INDEX (E.G,. KI67) Low High High HIGH ENDOCRINE SENSITIVITY First-line endocrine therapy alone ER+/HER2-: median PFS 14 months ER+/HER2+: median PFS 3 months Loss of PR HER2+ LOW ORR to 1st-line therapy AI: 40%; AI + CDK4/6i: 55% If there is accessibility/affordability, AI + CDK4/6i is a good alternative to chemotherapy in this setting If the predicted endocrine sensitivity is low, and the patient has a high tumor burden (not amounting to a crisis), chemotherapy may be warranted Kaufmann et al. J Clin Oncol, 2009; 27: ; Johnston et al. J Clin Oncol 2009; 27: ; Finn et al. NEJM 2016; 375: ; Hortobagyi et al NEJM 2016; 375: ; Goetz et al. J Clin Oncol 2017; 35: ; Turner et al. NEJM 2015; 373: ; Sledge et al. JCO 2017, 35(25):
22 Real world use of Chemotherapy vs Endocrine Therapy in HR+ Advanced Breast Cancers Global Oncology Monitor (physician-based syndicated patient record database) Post-menopausal, HR+/HER2- advanced/metastatic breast cancers 5 European countries (France, Germany, Italy, Spain, UK) and USA, Jan 2012 to Dec 2014 N = in Europe and in USA (every 3 months) Europe FIRST-LINE THERAPY USA Endocrine therapy only, 50-55% Chemotherapy only, 35% Chemotherapy + biologics Endocrine therapy only, 55-60% Chemotherapy only, 35-40% Endocrine therapy + biologics Characteristics of patients given first-line chemotherapy: Younger, less co-morbidity, more than bone metastases, more liver metastases, more prior adjuvant systemic therapy Lobbezoo et al. Ann Oncol 2016; 27: ; Bonotto et al. The Breast 2017: Andre et al. Cur Med Res and Opinion, 2014; 30(6); Caldeira et al. Oncol Ther 2016; 4(1);
23 Predicting Endocrine Resistance from Prior Treatment Response Trial of therapy may be one of the most reliable ways to determine endocrine sensitivity IMPACT (n=158); neoadjuvant tamoxifen or AI or combination Post-treatment Ki67 at 2 weeks predicts endocrine sensitivity better than baseline Ki67 RFS RFS Baseline Ki67 (tertiles) Post-treatment Ki67 at 2 weeks (tertiles) Dowsett et al. JNCI 2007; 99:
24 HIGH Predicting Endocrine Resistance from Prior Treatment Response ENDOCRINE SENSITIVITY LOW Prior Adjuvant Endocrine Therapy ADJUVANT ENDOCRINE THERAPY (5-10 years) Relapse within 2 years PRIMARY RESISTANCE (remote chance of response) Relapse after the first 2 years ACQUIRED RESISTANCE (low chance of response) Relapse 12 months of completing adjuvant endocrine therapy ACQUIRED RESISTANCE (some chance of response) Relapse >12 months of completing adjuvant endocrine therapy ENDOCRINE SENSITIVE (good chance of response) PALLIATIVE ENDOCRINE THERAPY Progress within 3 months PRIMARY RESISTANCE (remote chance of response) Progress between 3-6 months PRIMARY RESISTANCE (low chance of response) Progress after 6 months ACQUIRED RESISTANCE (some chance of response) Progress after 12 months ACQUIRED RESISTANCE (good chance of response) 2016 ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer
25 Special Imaging to Predict Endocrine Resistance 18 F-FES-PET N=90 ER+, HER2- breast cancers For endocrine therapy (63% AI, 22% AI + fulvestrant, 15% others) FDG-PET and FES-PET (16α[ 18 F]fluoro-17β-estradiol) imaging prior to endocrine therapy FES high PFS Low FDG P<0.001 FES low High FDG High FES FES high 3 kinds of tumor lesions - FDG low (indolent) - FDG high, FES high (likely endocrine sensitive) - FDG high, FES low (likely endocrine resistant) High FDG Low FES Kurland et al. Clin Cancer Res, 2016; 23(2):
26 Special Blood Tests (circulating tumor DNA [ctdna]) to Track Endocrine Resistance N=83 Metastatic breast cancer, first-line aromatase inhibitor 3-monthly collection of plasma for ctdna, until progression - digital droplet PCR and enhanced tagged amplicon sequencing Lead time to development of ESR1 mutations ESR1 mutations were detectable in plasma median 6.7 months before clinical progression Fribbens et al. Ann Oncol Oct 2017
27 Treatment Algorithm for Advanced Luminal Breast Cancers MOST LUMINAL BREAST CANCERS Start chemotherapy when endocrine resistance develops Start chemotherapy when endocrine resistance develops Start chemotherapy when endocrine resistance develops Best 1 st line Endocrine +/- Biological agent Best 2 nd line Endocrine Tx (+/- Biological agent)?3 rd /4 th /5 th line Endocrine Tx Chemotherapy Determining endocrine resistance Prior response to endocrine therapy Tumor factors (degree of ER/PR expression, HER2, grade, Ki67, etc) Future special tests (e.g., FES imaging, ctdna) Delay chemotherapy as long as possible with novel therapeutic strategies to overcome endocrine resistance HER2+ LUMINAL BREAST CANCER (for overall survival benefit) VISCERAL CRISIS/LIFE THREATENING DISEASE (for response) PREDICTED RELATIVE ENDOCRINE RESISTANCE + NARROW WINDOW OF OPPORTUNITY TO TREAT (for response) Start with Chemotherapy Sequential Endocrine Therapies +/- Biological agent until endocrine resistance Chemotherapy DIAGNOSIS Start chemotherapy when endocrine resistance develops DEATH
28 1910 Ad Good old chemotherapy can still be counted upon in advanced luminal breast cancer!
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationI SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationASCO 2018 Breast Cancer Highlights
ASCO 2018 Breast Cancer Highlights Angie DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology Co-Leader, Breast Cancer Program, Abramson
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationThe benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
The benefit of in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies Matthew P. Goetz¹, Joyce O Shaughnessy², George W. Sledge Jr.³, Miguel Martin⁴, Yong Lin⁵,
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationWhat do liquid biopsies offer us for breast cancer patients?
What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK Molecular Analysis of breast cancer Invasive
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationBreast Cancer Advanced Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Advanced Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch How to Guidelines and Consensus Breast Cancer Advanced Disease Prognosis Clonal (and diagnostic) evolution: Biopsy
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationEndocrine Therapy in Breast Cancer: State of the Art
Endocrine Therapy in Breast Cancer: State of the Art 12 AUG 2018 Mark Pegram, M.D. Susy Yuan-Huey Hung Professor of Oncology Associate Director for Clinical Research Director, Stanford Breast Oncology
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationCollaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer Lee Schwartzberg, MD, FACP Heather Greene, FNP, AOCNP West Cancer Center Memphis, Tennessee Learning Objectives
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationFulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella
Fulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella FULVESTRANT mechanism of action Carlson et al Clin Breast Cancer 2005; Howell Crit Rev Oncol Hematol 2016; Robertson et al Cancer Res 2001; De
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationCurrent standards and practice changing studies in Luminal ABC in 2017
Current standards and practice changing studies in Luminal ABC in 2017 F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationOptimization of Hormone Treatment: New Alternative Sequences
Optimization of Hormone Treatment: New Alternative Sequences ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationNovità e sequenze terapeutiche nel carcinoma mammario HER2 positivo Terapia neoadiuvante Claudio Zamagni
Novità e sequenze terapeutiche nel carcinoma mammario HER2 positivo Terapia neoadiuvante Claudio Zamagni Direttore SSD Oncologia Medica Addarii Policlinico S.Orsola-Malpighi Bologna Open questions in HER2+
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More information